Nika Pharmaceuticals Completes Acquisition
Ticker: NIKA · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1145604
| Field | Detail |
|---|---|
| Company | Nika Pharmaceuticals, Inc (NIKA) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, corporate-action
TL;DR
NIKA just closed a deal, formerly Centennial Growth Equities.
AI Summary
Nika Pharmaceuticals, Inc. announced on April 10, 2024, the completion of an acquisition. The company, formerly known as Centennial Growth Equities Inc. until July 24, 2001, is headquartered in Henderson, Nevada.
Why It Matters
This filing indicates a significant corporate action, signaling potential growth or strategic shifts for Nika Pharmaceuticals.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of an acquisition completion and does not inherently present immediate financial risks.
Key Players & Entities
- NIKA PHARMACEUTICALS, INC. (company) — Registrant
- CENTENNIAL GROWTH EQUITIES INC (company) — Former Company Name
- 20240410 (date) — Date of earliest event reported
- 20240415 (date) — Date of Report
- 702-326-3615 (phone_number) — Registrant's telephone number
FAQ
What type of acquisition did Nika Pharmaceuticals, Inc. complete?
The filing states the completion of an acquisition or disposition of assets, but does not specify the nature of the acquisition.
When was the acquisition completed?
The earliest event reported, indicating the completion of the acquisition, was on April 10, 2024.
What was Nika Pharmaceuticals, Inc. previously named?
Nika Pharmaceuticals, Inc. was formerly known as Centennial Growth Equities Inc.
What is the principal executive office address for Nika Pharmaceuticals, Inc.?
The principal executive offices are located at 2269 Merrimack Valley Avenue, Henderson, NV 89044.
What is the IRS Employer Identification Number for Nika Pharmaceuticals, Inc.?
The IRS Employer Identification Number is 90-0292940.
Filing Stats: 482 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-04-15 12:36:10
Filing Documents
- form8-k.htm (8-K) — 13KB
- exhibit21.htm (EX-21) — 1KB
- exhibit21x1x1.jpg (GRAPHIC) — 80KB
- exhibit21x2x1.jpg (GRAPHIC) — 66KB
- exhibit21x3x1.jpg (GRAPHIC) — 79KB
- 0001826466-24-000050.txt ( ) — 485KB
- nkph-20240410.xsd (EX-101.SCH) — 3KB
- nkph-20240410_lab.xml (EX-101.LAB) — 33KB
- nkph-20240410_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 Completion of Acquisition of Assets
Item 2.01 Completion of Acquisition of Assets. Pursuant to the terms of the merger of Nika BioTechnology, Inc. into Nika Pharmaceuticals, Inc., Nika Pharmaceuticals, Inc. has acquired the 40% stake in Nika Europe Ltd. that was owned by Nika BioTechnonoly, Inc. Dimitar Slavchev Savov who is an officer, director and majority shareholder in Nika Pharmaceuticals, Inc. was also officer, director and majority shareholder in Nika BioTechnology, Inc. prior to the merger, and serves as the general manager of Nika Europe Ltd where he holds a 20% stake. As a result of this transaction that was completed on April 10, 2024, Nika Pharmaceuticals, Inc now has an 80% stake in Nika Europe Ltd. On April 12, 2024, Nika Pharmaceuticals, Inc., through its subsidiary Nika Europe Ltd., acquired four technologies, three of which are for generic drugs and one for a dietary supplement. The technologies were purchased from Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology (AIPFPCB) for a total price of 45,000 BGN (equivalent to around 24,683 USD) that was paid by Dimitar Slavchev Savov who is an officer and director of Nika Pharmaceuticals, Inc. and the general manager of Nika Europe, Ltd. With the trade names pending, the three technologies for drugs in tablet form are scientifically named as MENTHYL VALERATE 0.06g, METAMIZOLE SODIUM 500mg, VINPOCETINE 10mg, with the dietary supplement named as TRIBULUS TERRESTRIS HERBA EXTRACTUM SICCUM 250mg.
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Ex21 Nika Europe Ltd. Certificate of Good Standing
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized. NIKA PHARMACEUTICALS, INC. Dated: April 15, 2024 By: /s/ Dimitar Slavchev Savov Dimitar Slavchev Savov Chief Executive Officer, Director